SHINE Medical

Greg Piefer, CEO of SHINE Medical Technologies, is flanked by sections of a production accelerator delivered to the Janesville company by Phoenix, of Monona. SHINE plans to use the accelerator to make radioisotopes for medical imaging tests, and has signed a deal with an institute in the Czech Republic to make a substance for treating cancer, as well.

When SHINE Medical Technologies begins operating, it will make not only a medical isotope badly needed for common diagnostic tests, but it will also manufacture an isotope for treating cancer for an organization in Prague.

SHINE has signed an agreement with the Institute of Organic Chemistry and Biochemistry of the CAS, a scientific research organization in the Czech Republic. SHINE will have a global, exclusive license for a new way of producing lutetium-177, a radioactive isotope being used to treat certain types of cancer.

The process involves separating rare earth elements, developed by a team headed by Miloslav Polášek at the Prague institute. “As a scientist, I am thrilled that the years in the lab may bring a real-world application, especially if it helps cancer patients,” Polášek said.

You have free articles remaining.

Become a Member

Earlier in May, SHINE broke ground for construction of a plant in Janesville where it will manufacture molybdenum-99, which decays into technetium-99m, an isotope used in millions of medical imaging procedures every year.

Production is expected to start in 2021.

Capital W: Plug in to Wisconsin politics

Subscribe to our Politics email!

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.